Chemotherapy – HealthQuill

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to extend the lives of patients who had undergone prior treatments.

Gilead’s end-stage confirmatory trials of bladder cancer drug fail

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.

by HealthQuill
October 21, 2024
0 Comments

Brazil became the 20th country in the world that has been validated by WHO to have eliminated lympatic filariasis as a public health problem.

Drugs Health Pharma

Brazil becomes 20th WHO-validated nation to eliminate lymphatic filariasis

Brazil became the 20th country in the world that has been validated by WHO to have eliminated lymphatic filariasis as a public health.

by HealthQuill
October 2, 2024
0 Comments

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in 27 member states and other nations.

Drugs Health Pharma

EC approves Merck’s bladder cancer combination therapy in adults

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.

by HealthQuill
September 3, 2024
0 Comments

The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed an extended nine months of survival.

Drugs Health Pharma

AstraZeneca’s medicine for non-small lung cancer gets EU nod

HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.

by HealthQuill
July 5, 2024
0 Comments

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

by HealthQuill
June 4, 2024
0 Comments

AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival

Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.

by HealthQuill
June 3, 2024
0 Comments

The US Food and Drug Administration has cleared Orchard Therapeutics’s gene therapy to treat a disease affecting the brain and nervous system in children — the regulator’s first ever for the disorder.

Drugs Health Pharma

FDA green lights first-ever therapy for rare genetic disease in kids

HQ Team March 19, 2023: The US Food and Drug Administration has cleared Orchard Therapeutics’s gene therapy to treat a disease affecting the.

by HealthQuill
March 19, 2024
0 Comments

The USFDA has cleared AstraZeneca’s lung cancer drug Tagrisso with chemotherapy for treatment in adult patients.

Drugs Health Pharma

AstraZeneca’s non-small lung cancer therapy gets FDA clearance

HQ Team February 17, 2024: The USFDA has cleared AstraZeneca’s Tagrisso with chemotherapy for treatment in adult patients with non-small cell lung cancer..

by HealthQuill
February 17, 2024
0 Comments

Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to evaluate the combination of the company's breast cancer vaccine with Merck’s Keytruda (pembrolizumab) immunotherapy.

Drugs Health Medical Pharma

GSK’s Jemperli shows promise in treating endometrial cancer

HQ Team October 30, 2023: GSK plc has announced significant findings from a phase III trial trial for Jemperli (dostarlimab), a potential treatment for.